Merck drug results suggest it will extend its lead in lung cancer; Bristol-Myers shares drop – CNBC


CNBC

Merck drug results suggest it will extend its lead in lung cancer; Bristol-Myers shares drop
CNBC
Immunotherapy drugs from Bristol-Myers Squibb and Merck both topped Wall Street's expectations in highly anticipated clinical trial results presented Monday in advanced lung cancer. Merck surpassed expectations by even more than Bristol. Merck shares ...
Merck, Bristol-Myers immunotherapies impress in key lung cancer trialsReuters
Merck shares rise after beating rivals' lung cancer resultsMarketWatch
In a monster showing, Merck's Keytruda combo slashes lung cancer death risk by halfFiercePharma
Bloomberg -Financial Times -Seeking Alpha -Xconomy
all 27 news articles »